Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade
Aim: We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for evaluation of the prognosis of intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer criteria stage B, BCLC-B). Patients an...
Gespeichert in:
Veröffentlicht in: | Oncology 2016, Vol.91 (3), p.153-161 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 161 |
---|---|
container_issue | 3 |
container_start_page | 153 |
container_title | Oncology |
container_volume | 91 |
creator | Hiraoka, Atsushi Kumada, Takashi Nouso, Kazuhiro Tsuji, Kunihiko Itobayashi, Ei Hirooka, Masashi Kariyama, Kazuya Ishikawa, Toru Tada, Toshifumi Toyoda, Hidenori Kawasaki, Hideki Hiasa, Yoichi Michitaka, Kojiro |
description | Aim: We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for evaluation of the prognosis of intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer criteria stage B, BCLC-B). Patients and Methods: We enrolled 754 naïve BCLC-B patients (multiple tumors) and retrospectively analyzed their clinical features [surgical resection (hepatectomy), n = 170; radiofrequency ablation (RFA), n = 110; percutaneous ethanol injection, n = 7; transcatheter arterial chemoembolization, n = 396; others, n = 25; best supportive care, n = 46]. Four sub-groups were defined for the Modified Intermediate Stage of Liver Cancer (MICAN) criteria as follows: B1 (ALBI-1/within up-to-7 criteria), B2 (ALBI-2/within up-to-7 criteria), B3 (ALBI-1 and ALBI-2/multiple and beyond up-to-7 criteria), and B4 (ALBI-3/any). Results: The median survival time of patients classified as B1 (n = 94), B2 (n = 175), B3 (n = 452), and B4 (n = 33) was 65.1, 48.1, 29.6, and 14.6 months, respectively (p < 0.01 for each). Those in B1 treated with hepatectomy and RFA comprised 67.0%, while that ratio was 51.4% in B2, 28.3% in B3, and 12.1% in B4. Conclusion: The MICAN criteria based on ALBI grade are simple and useful for prediction of prognosis and therapy decision-making in the heterogeneous population of BCLC-B patients. |
doi_str_mv | 10.1159/000447061 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_healthsolutions_A637398563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A637398563</galeid><sourcerecordid>A637398563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c318t-5918aceee04a515573aff5efa6fdab032f5dc05e391c457fe9c4566ee10a9c243</originalsourceid><addsrcrecordid>eNo90U1P3DAQBmCrApWF9tB7hXJC7SHUjj-SHJdVWZAQrbTdczRJxsGtEwc7FuLfk-0ue5rLMx-al5AvjF4zJssflFIhcqrYB7JgIuMpzXh2QhaUcppmgokzch7C35nlUqiP5CzLucqUKhek--3d6AK2ySO-JJtYp2vv4miGLtHOJ_fDhL7H1sCE6WaCDpM7HGFyDVobLfhkBb4xg-sh2YZd19LWsTdDemOs8bE2Q7L20OIncqrBBvx8qBdke_vzz-ouffi1vl8tH9KGs2JKZckKaBCRCpBMypyD1hI1KN1CTXmmZdtQibxkjZC5xnIuSiEyCmWTCX5Bvu3njt49RwxT1ZuwOxYGdDFUrGAF53mh-Eyv9rQDi9UTgp2egrNxMm4I1VLxnJeF_A-_72HjXQgedTV604N_rRitdgFUxwBme3nYH-v5b0f5_vEZfN2Df-A79Edw6H8Dp2-JSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818337863</pqid></control><display><type>article</type><title>Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade</title><source>Karger Journals</source><source>MEDLINE</source><creator>Hiraoka, Atsushi ; Kumada, Takashi ; Nouso, Kazuhiro ; Tsuji, Kunihiko ; Itobayashi, Ei ; Hirooka, Masashi ; Kariyama, Kazuya ; Ishikawa, Toru ; Tada, Toshifumi ; Toyoda, Hidenori ; Kawasaki, Hideki ; Hiasa, Yoichi ; Michitaka, Kojiro</creator><creatorcontrib>Hiraoka, Atsushi ; Kumada, Takashi ; Nouso, Kazuhiro ; Tsuji, Kunihiko ; Itobayashi, Ei ; Hirooka, Masashi ; Kariyama, Kazuya ; Ishikawa, Toru ; Tada, Toshifumi ; Toyoda, Hidenori ; Kawasaki, Hideki ; Hiasa, Yoichi ; Michitaka, Kojiro</creatorcontrib><description>Aim: We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for evaluation of the prognosis of intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer criteria stage B, BCLC-B). Patients and Methods: We enrolled 754 naïve BCLC-B patients (multiple tumors) and retrospectively analyzed their clinical features [surgical resection (hepatectomy), n = 170; radiofrequency ablation (RFA), n = 110; percutaneous ethanol injection, n = 7; transcatheter arterial chemoembolization, n = 396; others, n = 25; best supportive care, n = 46]. Four sub-groups were defined for the Modified Intermediate Stage of Liver Cancer (MICAN) criteria as follows: B1 (ALBI-1/within up-to-7 criteria), B2 (ALBI-2/within up-to-7 criteria), B3 (ALBI-1 and ALBI-2/multiple and beyond up-to-7 criteria), and B4 (ALBI-3/any). Results: The median survival time of patients classified as B1 (n = 94), B2 (n = 175), B3 (n = 452), and B4 (n = 33) was 65.1, 48.1, 29.6, and 14.6 months, respectively (p < 0.01 for each). Those in B1 treated with hepatectomy and RFA comprised 67.0%, while that ratio was 51.4% in B2, 28.3% in B3, and 12.1% in B4. Conclusion: The MICAN criteria based on ALBI grade are simple and useful for prediction of prognosis and therapy decision-making in the heterogeneous population of BCLC-B patients.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000447061</identifier><identifier>PMID: 27362669</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Aged ; Albumin ; Bilirubin ; Bilirubin - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Care and treatment ; Catheter Ablation ; Chemoembolization, Therapeutic ; Clinical Decision-Making - methods ; Clinical Study ; Diagnosis ; Female ; Health aspects ; Hepatectomy ; Hepatocellular carcinoma ; Humans ; Identification and classification ; Liver Neoplasms - blood ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Serum Albumin - metabolism ; Survival Rate</subject><ispartof>Oncology, 2016, Vol.91 (3), p.153-161</ispartof><rights>2016 S. Karger AG, Basel</rights><rights>2016 S. Karger AG, Basel.</rights><rights>COPYRIGHT 2016 S. Karger AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c318t-5918aceee04a515573aff5efa6fdab032f5dc05e391c457fe9c4566ee10a9c243</citedby><cites>FETCH-LOGICAL-c318t-5918aceee04a515573aff5efa6fdab032f5dc05e391c457fe9c4566ee10a9c243</cites><orcidid>0000-0003-1989-0480 ; 0000-0003-3996-7502 ; 0000-0002-0976-6761 ; 0000-0002-1652-6168 ; 0000-0003-2211-495X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27362669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hiraoka, Atsushi</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Nouso, Kazuhiro</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Itobayashi, Ei</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Kariyama, Kazuya</creatorcontrib><creatorcontrib>Ishikawa, Toru</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kawasaki, Hideki</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><creatorcontrib>Michitaka, Kojiro</creatorcontrib><title>Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Aim: We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for evaluation of the prognosis of intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer criteria stage B, BCLC-B). Patients and Methods: We enrolled 754 naïve BCLC-B patients (multiple tumors) and retrospectively analyzed their clinical features [surgical resection (hepatectomy), n = 170; radiofrequency ablation (RFA), n = 110; percutaneous ethanol injection, n = 7; transcatheter arterial chemoembolization, n = 396; others, n = 25; best supportive care, n = 46]. Four sub-groups were defined for the Modified Intermediate Stage of Liver Cancer (MICAN) criteria as follows: B1 (ALBI-1/within up-to-7 criteria), B2 (ALBI-2/within up-to-7 criteria), B3 (ALBI-1 and ALBI-2/multiple and beyond up-to-7 criteria), and B4 (ALBI-3/any). Results: The median survival time of patients classified as B1 (n = 94), B2 (n = 175), B3 (n = 452), and B4 (n = 33) was 65.1, 48.1, 29.6, and 14.6 months, respectively (p < 0.01 for each). Those in B1 treated with hepatectomy and RFA comprised 67.0%, while that ratio was 51.4% in B2, 28.3% in B3, and 12.1% in B4. Conclusion: The MICAN criteria based on ALBI grade are simple and useful for prediction of prognosis and therapy decision-making in the heterogeneous population of BCLC-B patients.</description><subject>Aged</subject><subject>Albumin</subject><subject>Bilirubin</subject><subject>Bilirubin - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Care and treatment</subject><subject>Catheter Ablation</subject><subject>Chemoembolization, Therapeutic</subject><subject>Clinical Decision-Making - methods</subject><subject>Clinical Study</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Serum Albumin - metabolism</subject><subject>Survival Rate</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90U1P3DAQBmCrApWF9tB7hXJC7SHUjj-SHJdVWZAQrbTdczRJxsGtEwc7FuLfk-0ue5rLMx-al5AvjF4zJssflFIhcqrYB7JgIuMpzXh2QhaUcppmgokzch7C35nlUqiP5CzLucqUKhek--3d6AK2ySO-JJtYp2vv4miGLtHOJ_fDhL7H1sCE6WaCDpM7HGFyDVobLfhkBb4xg-sh2YZd19LWsTdDemOs8bE2Q7L20OIncqrBBvx8qBdke_vzz-ouffi1vl8tH9KGs2JKZckKaBCRCpBMypyD1hI1KN1CTXmmZdtQibxkjZC5xnIuSiEyCmWTCX5Bvu3njt49RwxT1ZuwOxYGdDFUrGAF53mh-Eyv9rQDi9UTgp2egrNxMm4I1VLxnJeF_A-_72HjXQgedTV604N_rRitdgFUxwBme3nYH-v5b0f5_vEZfN2Df-A79Edw6H8Dp2-JSw</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Hiraoka, Atsushi</creator><creator>Kumada, Takashi</creator><creator>Nouso, Kazuhiro</creator><creator>Tsuji, Kunihiko</creator><creator>Itobayashi, Ei</creator><creator>Hirooka, Masashi</creator><creator>Kariyama, Kazuya</creator><creator>Ishikawa, Toru</creator><creator>Tada, Toshifumi</creator><creator>Toyoda, Hidenori</creator><creator>Kawasaki, Hideki</creator><creator>Hiasa, Yoichi</creator><creator>Michitaka, Kojiro</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1989-0480</orcidid><orcidid>https://orcid.org/0000-0003-3996-7502</orcidid><orcidid>https://orcid.org/0000-0002-0976-6761</orcidid><orcidid>https://orcid.org/0000-0002-1652-6168</orcidid><orcidid>https://orcid.org/0000-0003-2211-495X</orcidid></search><sort><creationdate>2016</creationdate><title>Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade</title><author>Hiraoka, Atsushi ; Kumada, Takashi ; Nouso, Kazuhiro ; Tsuji, Kunihiko ; Itobayashi, Ei ; Hirooka, Masashi ; Kariyama, Kazuya ; Ishikawa, Toru ; Tada, Toshifumi ; Toyoda, Hidenori ; Kawasaki, Hideki ; Hiasa, Yoichi ; Michitaka, Kojiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c318t-5918aceee04a515573aff5efa6fdab032f5dc05e391c457fe9c4566ee10a9c243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Albumin</topic><topic>Bilirubin</topic><topic>Bilirubin - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Care and treatment</topic><topic>Catheter Ablation</topic><topic>Chemoembolization, Therapeutic</topic><topic>Clinical Decision-Making - methods</topic><topic>Clinical Study</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Serum Albumin - metabolism</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hiraoka, Atsushi</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Nouso, Kazuhiro</creatorcontrib><creatorcontrib>Tsuji, Kunihiko</creatorcontrib><creatorcontrib>Itobayashi, Ei</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Kariyama, Kazuya</creatorcontrib><creatorcontrib>Ishikawa, Toru</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kawasaki, Hideki</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><creatorcontrib>Michitaka, Kojiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiraoka, Atsushi</au><au>Kumada, Takashi</au><au>Nouso, Kazuhiro</au><au>Tsuji, Kunihiko</au><au>Itobayashi, Ei</au><au>Hirooka, Masashi</au><au>Kariyama, Kazuya</au><au>Ishikawa, Toru</au><au>Tada, Toshifumi</au><au>Toyoda, Hidenori</au><au>Kawasaki, Hideki</au><au>Hiasa, Yoichi</au><au>Michitaka, Kojiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2016</date><risdate>2016</risdate><volume>91</volume><issue>3</issue><spage>153</spage><epage>161</epage><pages>153-161</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Aim: We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for evaluation of the prognosis of intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Cancer criteria stage B, BCLC-B). Patients and Methods: We enrolled 754 naïve BCLC-B patients (multiple tumors) and retrospectively analyzed their clinical features [surgical resection (hepatectomy), n = 170; radiofrequency ablation (RFA), n = 110; percutaneous ethanol injection, n = 7; transcatheter arterial chemoembolization, n = 396; others, n = 25; best supportive care, n = 46]. Four sub-groups were defined for the Modified Intermediate Stage of Liver Cancer (MICAN) criteria as follows: B1 (ALBI-1/within up-to-7 criteria), B2 (ALBI-2/within up-to-7 criteria), B3 (ALBI-1 and ALBI-2/multiple and beyond up-to-7 criteria), and B4 (ALBI-3/any). Results: The median survival time of patients classified as B1 (n = 94), B2 (n = 175), B3 (n = 452), and B4 (n = 33) was 65.1, 48.1, 29.6, and 14.6 months, respectively (p < 0.01 for each). Those in B1 treated with hepatectomy and RFA comprised 67.0%, while that ratio was 51.4% in B2, 28.3% in B3, and 12.1% in B4. Conclusion: The MICAN criteria based on ALBI grade are simple and useful for prediction of prognosis and therapy decision-making in the heterogeneous population of BCLC-B patients.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>27362669</pmid><doi>10.1159/000447061</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1989-0480</orcidid><orcidid>https://orcid.org/0000-0003-3996-7502</orcidid><orcidid>https://orcid.org/0000-0002-0976-6761</orcidid><orcidid>https://orcid.org/0000-0002-1652-6168</orcidid><orcidid>https://orcid.org/0000-0003-2211-495X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0030-2414 |
ispartof | Oncology, 2016, Vol.91 (3), p.153-161 |
issn | 0030-2414 1423-0232 |
language | eng |
recordid | cdi_gale_healthsolutions_A637398563 |
source | Karger Journals; MEDLINE |
subjects | Aged Albumin Bilirubin Bilirubin - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Care and treatment Catheter Ablation Chemoembolization, Therapeutic Clinical Decision-Making - methods Clinical Study Diagnosis Female Health aspects Hepatectomy Hepatocellular carcinoma Humans Identification and classification Liver Neoplasms - blood Liver Neoplasms - pathology Liver Neoplasms - therapy Male Middle Aged Neoplasm Staging Prognosis Retrospective Studies Serum Albumin - metabolism Survival Rate |
title | Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T02%3A22%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proposed%20New%20Sub-Grouping%20for%20Intermediate-Stage%20Hepatocellular%20Carcinoma%20Using%20Albumin-Bilirubin%20Grade&rft.jtitle=Oncology&rft.au=Hiraoka,%20Atsushi&rft.date=2016&rft.volume=91&rft.issue=3&rft.spage=153&rft.epage=161&rft.pages=153-161&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000447061&rft_dat=%3Cgale_proqu%3EA637398563%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1818337863&rft_id=info:pmid/27362669&rft_galeid=A637398563&rfr_iscdi=true |